Glucagon‐like peptide (GLP)‐1 and leptin concentrations in obese patients with Type 2 diabetes mellitus

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Diabetic Medicine

• Publication date

  2000-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1464-5491.2000.00367.xPMID 11110504
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Elevation of plasma leptin concentrations in obese hyperinsulinaemic hypothyroidism before and after treatment

  1999cited by this paper
• Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.

  1999cited by this paper
• Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans.

  1999cited by this paper
• Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic.

  1999cited by this paper
• Interaction of insulin, glucagon-like peptide 1, gastric inhibitory polypeptide, and appetite in response to intraduodenal carbohydrate.

  1998cited by this paper
• Effects of Glucagon-Like Peptide 1 (7–36 Amide) on Glucose Kinetics during Somatostatin-Induced Suppression of Insulin Secretion in Healthy Men

  1998cited by this paper
• Relationship between leptin and oestrogens in healthy women.

  1998cited by this paper
• Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.

  1997cited by this paper
• Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans.

  1997cited by this paper
• Serum leptin concentration, obesity, and insulin resistance in Western Samoans: cross sectional study

  1996cited by this paper
• Attenuated GLP-1 secretion in obesity: cause or consequence?

  1996cited by this paper
• Acute and Chronic Effect of Insulin on Leptin Production in Humans: Studies In Vivo and In Vitro

  1996cited by this paper
• The Effect of Glucagon-Like Peptide I (GLP-I) on Glucose Elimination in Healthy Subjects Depends on the Pancreatic Glucoregulatory Hormones

  1996cited by this paper
• GLP‐1 in NIDDM

  1996cited by this paper
• Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.

  1996cited by this paper
• Radiommunological measurement of leptin in plasma of obese and diabetic human subjects.

  1996cited by this paper
• Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day.

  1996cited by this paper
• Leptin Concentrations in Diabetic and Nondiabetic Mexican-Americans

  1996cited by this paper
• Human Studies with Glucagon‐like‐peptide‐1: Potential of the Gut Hormone for Clinical Use

  1996cited by this paper
• Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM

  1996cited by this paper
• Antibiotic Treatment for Uncomplicated Neuropathic Forefoot Ulcers in Diabetes: a Controlled Trial

  1996cited by this paper
• Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM

  1995cited by this paper
• Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients.

  1995cited by this paper
• Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.

  1994cited by this paper
• Hypersecretion of Truncated Glucagon‐like Peptide‐1 and Gastric Inhibitory Polypeptide in Obese Patients

  1993cited by this paper
• Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients

  1992cited by this paper
• Hyperglycemia but not hyperinsulinemia prevents the secretion of glucagon-like peptide-1 (7–36amide) stimulated by fat ingestion

  1992cited by this paper
• Hyperglycaemia but not hyperinsulinaemia prevents the secretion of glucagon-like peptide-1 (7-36 amide) stimulated by fat ingestion

  1991cited by this paper
• Glucose clamp technique: a method for quantifying insulin secretion and resistance.

  1979cited by this paper

• The commercial availability of plant-based phytochemical components used in GLP-1 inhibition for the treatment of type-2 diabetes

  2025cites this paper
• Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders

  2025cites this paper
• The efficacy and safety of qiwei baizhu san in the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis

  2025cites this paper
• Chronotropic Responses to GLP-1 Receptor Agonists and Sitagliptin in Atria From Diabetic Rats

  2024cites this paper
• Postprandial glycemic response to a high-protein diabetes-specific nutritional shake compared to isocaloric instant oatmeal in people with type 2 diabetes: a randomized, controlled, crossover trial

  2024cites this paper
• Gut microbes and food reward: From the gut to the brain

  2022cites this paper
• Altered chronic glycemic control in a clinically relevant model of rat thoracic spinal contusion

  2022cites this paper
• A new synthetic dual agonist of GPR120/GPR40 induces GLP-1 secretion and improves glucose homeostasis in mice.

  2021cites this paper
• Increased of fasting active glucagon-like peptide-1 is associated with insulin resistance in patients with hypertriglyceridemia

  2021cites this paper
• The Emerging Role of Polyphenols in the Management of Type 2 Diabetes

  2021cites this paper
• Glucolipotoxicity and GLP-1 secretion

  2021cites this paper
• Effects of gypenosides on enteroendocrine L-cell function and GLP-1 secretion

  2020influential citation
• Evaluation of insulin resistance in overweight and obese dogs

  2020influential citation
• Intestinal Hormones

  2020cites this paper
• Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes

  2020cites this paper
• Effect of Short-Term Increase in Meal Frequency on Glucose Metabolism in Individuals with Normal Glucose Tolerance or Impaired Fasting Glucose: A Randomized Crossover Clinical Trial

  2019cites this paper
• Changes in Host Response to Mycobacterium tuberculosis Infection Associated With Type 2 Diabetes: Beyond Hyperglycemia

  2019cites this paper
• Role of Glucagon-Like Peptide-1 in Appetite Regulation in Patients with Morbid Obesity and Leptin Resistance

  2019cites this paper
• A Novel Dipeptidyl Peptidase IV Inhibitory Tea Peptide Improves Pancreatic β-Cell Function and Reduces α-Cell Proliferation in Streptozotocin-Induced Diabetic Mice

  2019cites this paper
• Diabetes, Incretin therapy and thoracic aortic aneurysm-what does the evidence show?

  2019cites this paper
• Relationship between the insulin resistance and circulating predictive biochemical markers in metabolic syndrome among young adults in western Algeria.

  2019cites this paper
• The effect of diet, adiposity, and weight loss on the secretion of incretin hormones in cats.

  2018cites this paper
• Influence of Diet and Gender on Plasma DPP4 Activity and GLP-1 in Patients with Metabolic Syndrome: An Experimental Pilot Study

  2018cites this paper
• Chapter 3 – Glucagon-Like Peptide 1 and Human Obesity

  2018cites this paper
• Glucagon-like peptide-1 profile during oral glucose tolerance test in young people

  2017cites this paper
• Enteroendocrine Cells: Metabolic Relays between Microbes and Their Host.

  2017cites this paper
• Dipeptidyl Peptidase-4 and Adolescent Idiopathic Scoliosis: Expression in Osteoblasts

  2017cites this paper
• Partial ileal bypass affords protection from onset of type 2 diabetes.

  2017cites this paper
• Influence of supervised training and a hypocaloric macronutrient scheduled diet vs a hypocaloric macronutrient scheduled diet alone on energy regulating hormones in overweight and obese men ages 35-55: a randomized control trial

  2017cites this paper
• IL-6–Type Cytokine Signaling in Adipocytes Induces Intestinal GLP-1 Secretion

  2017cites this paper
• Mechanisms for the cardiovascular effects of glucagon‐like peptide‐1

  2016cites this paper
• Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity

  2016cites this paper
• Fasting serum glucagon-like peptide-1 concentrations in obese patients with acanthosis nigricans : a pilot study

  2016cites this paper
• The regulation of function, growth and survival of GLP-1-producing L-cells.

  2016cites this paper
• Split Ssp DnaB mini‐intein‐mediated production of recombinant human glucagon‐like peptide‐1/7‐36

  2015cites this paper
• Inteins—A focus on the biotechnological applications of splicing-promoting proteins

  2015cites this paper
• Metabolic Mechanisms in Obesity and Type 2 Diabetes: Insights from Bariatric/Metabolic Surgery

  2015cites this paper
• Stimulus-Section Coupling in Endocrine Cell Models

  2015cites this paper
• Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

  2015cites this paper
• Effects of Glucagon-like Peptide-1 in Diabetic Rat Small Resistance Arteries

  2014cites this paper
• Effects on GLP-1, PYY, and leptin by direct stimulation of terminal ileum and cecum in humans: implications for ileal transposition.

  2014cites this paper
• THE EFFECTS OF AEROBIC TRAINING AND ARBUTIN ON GLP1 AND GLP1R IN DIABETES RATS

  2014cites this paper
• GLP-1R activation for the treatment of stroke: Updating and future perspectives

  2014cites this paper
• Proteomics approaches to understand linkage between Alzheimer's disease and type 2 diabetes mellitus.

  2014cites this paper
• Pathophysiology of diabetes mellitus type 2: beyond the duo "insulin resistance-secretion deficit".

  2013cites this paper
• Circulating glucagon-like peptide-1 increases in response to short-term overfeeding in men

  2013cites this paper
• Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration.

  2013cites this paper
• An investigation of perinatal polychlorinated biphenyl exposure on body composition and glucose homeostasis

  2013cites this paper
• Bone: Incretin Hormones Perceiver or Receiver?

  2012cites this paper
• Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis

  2012cites this paper
• Sustained Exendin-4 Secretion through Gene Therapy Targeting Salivary Glands in Two Different Rodent Models of Obesity/Type 2 Diabetes

  2012cites this paper
• Níveis séricos de leptina na obesidade e associação com fatores de risco da Síndrome metabólica

  2012cites this paper
• Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus.

  2012cites this paper
• Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non‐alcoholic fatty liver disease

  2012cites this paper
• Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus

  2012cites this paper
• Molecular regulation of hormone secretion, growth and apoptosis of GLP-1-producing cells

  2012cites this paper
• Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells

  2012cites this paper
• Gut as an Endocrine Organ: The Role of Nutrient Sensing in Energy Metabolism

  2011cites this paper
• Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities

  2011cites this paper
• PPARβ/δ activation induces enteroendocrine L cell GLP-1 production.

  2011cites this paper
• From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy

  2011cites this paper
• The diabetic cardiomyopathy

  2011cites this paper
• Predicting response to incretin-based therapy

  2011cites this paper
• The Effect of Insulin and Insulin Resistance on Glucagon-like Peptide-1 Secretion from the Intestinal L Cell

  2010influential citation
• Relationship between GLP‐1 levels and dipeptidyl peptidase‐4 activity in different glucose tolerance conditions

  2010cites this paper
• The role of leptin in the regulation of glucose homeostasis

  2010cites this paper
• Metabolic Disturbances in Diabetes

  2010cites this paper
• Bile-induced secretion of glucagon-like peptide-1 4 Pathophysiological implications in type 2 diabetes ? 5 6 7

  2010cites this paper
• Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?

  2010cites this paper
• Oral glucose leads to a differential response in glucose, insulin, and GLP-1 in lean versus obese cats.

  2010cites this paper
• Incretins and the specific mechanism of action of liraglutide, the first applicable human glucagon-like peptide 1 analog in the treatment of type 2 diabetes

  2010cites this paper
• Insulin-regulated glucagon-like peptide-1 release from L cells: actin' out.

  2009cites this paper
• Glucagon−like Peptide−1 and−2 Levels in Children with Diabetic Ketoacidosis

  2009cites this paper
• Glucagon-like peptide-1 response to meals and post-prandial hyperglycemia in Type 2 diabetic patients

  2009cites this paper
• Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell.

  2009cites this paper
• The entero-insular axis: implications for human metabolism

  2008cites this paper
• Serum leptin and its relationship with metabolic variables in Arabs with type 2 diabetes mellitus

  2008cites this paper
• Sitagliptin: a novel agent for the management of type 2 diabetes mellitus.

  2008cites this paper
• Applied nutritional investigation Effect of two carbohydrate-modified tube-feeding formulas on metabolic responses in patients with type 2 diabetes

  2008cites this paper
• Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk.

  2008cites this paper
• Effect of two carbohydrate-modified tube-feeding formulas on metabolic responses in patients with type 2 diabetes.

  2008cites this paper
• Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1

  2008cites this paper
• Adiponectin and leptin: Potential tools in the differential diagnosis of pediatric diabetes?

  2007cites this paper
• Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia.

  2007cites this paper
• Intestinal peptides and ethnic differences in insulin secretion

  2006cites this paper
• Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus

  2006cites this paper
• Exenatide: A Novel Approach for Treatment of Type 2 Diabetes

  2006cites this paper
• Targeting postprandial hyperglycemia.

  2006cites this paper
• Glucagon-Like Peptide 1 Secretion by the L-Cell

  2006influential citation
• Glucagon-Like Peptide 1 Secretion by the L-Cell The View From Within

  2006influential citation
• Engineered beta-cells secreting dipeptidyl peptidase IV-resistant glucagon-like peptide-1 show enhanced glucose-responsiveness.

  2005cites this paper
• Glucagon-like peptide 1 (GLP-1) and metabolic diseases

  2005cites this paper
• Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.

  2005cites this paper
• Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.

  2005cites this paper
• Effects of liraglutide (NN2211), a long‐acting GLP‐1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes

  2005cites this paper
• Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

  2005cites this paper
• Nutrient-stimulated GLP-1 Release in Normal-weight Men and Women

  2005cites this paper
• Prognostic Factors Following Curative Resection for Pancreatic Adenocarcinoma

  2004cites this paper
• Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease.

  2004cites this paper
• Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes.

  2004cites this paper